SLDB
Solid Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SLDB
Solid Biosciences Inc.
A life sciences company focused on treatments for Duchenne
500 Rutherford Avenue, Third Floor, Charlestown, MA 02129
--
Solid Biosciences Inc., formerly known as SOLID Ventures Management, LLC, was established in March 2013 as a Delaware limited liability company. The Company is a life sciences company focused on advancing a portfolio of current and future gene therapy drug candidates, which the Company refers to collectively as drug candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, or Duchenne, SGT-501 for the treatment of catecholaminergic pleomorphic ventricular tachycardia (CPVT), and additional assets for the treatment of heart and disease, which are at different stages of development with different levels of investment. The company is advancing a diverse pipeline involving rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management and care. Patient-centered and founded by those directly influenced by Duchenne, the company's mission is to improve the daily lives of patients suffering from these devastating diseases.
Company Financials
EPS
SLDB has released its 2025 Q3 earnings. EPS was reported at -0.48, versus the expected -0.44, missing expectations. The chart below visualizes how SLDB has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
